The utility of syndecan-1 circulating levels as a biomarker in patients with previous or active COVID-19: a systematic review and meta-analysis

BMC Infectious Diseases, Journal Year: 2023, Volume and Issue: 23(1)

Published: Aug. 4, 2023

Abstract Background With the emergence of coronavirus disease 2019 (COVID-19), several blood biomarkers have been identified, including endothelial biomarker syndecan-1, a surface proteoglycan. In current systematic review and meta-analysis, we aimed to assess diagnostic prognostic role syndecan-1 in COVID-19. Methods PubMed, Embase, Scopus, Web Science, as international databases, were searched for relevant studies measuring levels COVID-19 patients, convalescents, healthy control subjects, patients with different severities and/or poor outcomes. Random-effect meta-analysis was performed using STATA calculate standardized mean difference (SMD) 95% confidence interval (CI) comparison between subjects or convalescents controls. Results After screening by title/abstract full text, 17 included final review. Meta-analysis compared revealed that had significantly higher (SMD 1.53, CI 0.66 2.41, P < 0.01). contrast, convalescent did not show significant non-convalescents 0.08, -0.63 0.78, = 0.83). Regarding severity, two reported more severe forms associated increased levels. Moreover, who died from survivors 1.22, 0.10 2.33, 0.03). Conclusion Circulating level can be used dysfunction COVID-19, it instances disease. Further larger are needed confirm these findings further enlighten clinical settings.

Language: Английский

---

Immuno-Modulatory Effects of Dexamethasone in Severe COVID-19—A Swedish Cohort Study

Biomedicines, Journal Year: 2023, Volume and Issue: 11(1), P. 164 - 164

Published: Jan. 9, 2023

Dexamethasone (Dex) has been shown to decrease mortality in severe coronavirus disease 2019 (COVID-19), but the mechanism is not fully elucidated. We aimed investigate physiological and immunological effects associated with Dex administration patients admitted intensive care COVID-19. A total of 216 adult COVID-19 were included-102 (47%) received Dex, 6 mg/day for 10 days, 114 (53%) did not. Standard laboratory parameters, plasma expression cytokines, endothelial markers, immunoglobulin (Ig) IgA, IgM, IgG against SARS-CoV-2 analyzed post-admission care. Patients treated had higher blood glucose lower lactate, cortisol, IgG, D-dimer, syndecan-1, E-selectin less organ support than those who receive (Without-Dex). There was an association between treatment IL-17A, macrophage inflammatory protein 1 alpha, syndecan-1 as well predicting 30-day mortality. Among a subgroup early, within 14 days debut, adjusted risk 0.4 (95% CI 0.2-0.8), i.e., 40% compared Without-Dex. cohort critically ill resulted altered physiologic responses, some which

Language: Английский

---

CLINICAL VALUE OF SYNDECAN-1 LEVELS IN TRAUMA BRAIN INJURY: A META-ANALYSIS

Shock, Journal Year: 2023, Volume and Issue: unknown

Published: Oct. 13, 2023

Background: Traumatic brain injury (TBI) is a head trauma usually associated with death and endothelial glycocalyx damage. Syndecan-1 (SDC-1)-a biomarker of degradation-has rarely been reported in meta-analyses to determine the clinical prognostic value TBI patients. Methods: We looked into PubMed, EMBASE, Cochrane Library, Web Science databases from January 1, 1990, May 2023, identify eligible studies. A meta-analysis was conducted using RevMan 5.4 Stata 16.0 search terms "SDC-1" "traumatic injury." Results: The present study included five studies total 640 enrolled patients included. concentrations were higher isotrauma group than non-TBI (standardized mean difference [SMD] = 0.52; 95% CI: 0.03-1.00; P 0.04). Subgroup analysis revealed statistical significance when comparing SDC-1 level multitrauma (TBI + other injuries) (SMD 0.74; 0.42-1.05; < 0.001), coagulopathy (+) early coagulopathy) (-) 1.75; 0.41-3.10; 0.01). Isotrauma at risk 30-day in-hospital mortality (odds ratio 3.32; 1.67-6.60; 0.0006). Conclusion: This suggests that could be endotheliopathy TBI, as it increased There need for additional research use especially

Language: Английский

---

Longitudinal Assessment of Plasma Syndecan-1 Predicts 60-Day Mortality in Patients with COVID-19

Journal of Clinical Medicine, Journal Year: 2023, Volume and Issue: 12(2), P. 552 - 552

Published: Jan. 10, 2023

Background: Endotheliopathy is a common pathologic finding in patients with acute and long COVID-19. It may be associated disease severity predispose to long-term complications. Plasma levels of proteoglycan, syndecan-1, are found significantly elevated COVID-19, but its roles assessing predicting outcome not fully understood. Methods: A total 124 consecutive hospitalized SARS-CoV-2 infection were prospectively enrolled blood samples collected on admission (T1), 3−4 days following treatment (T2), 1−2 prior discharge or death (T3). syndecan-1 determined using an immunosorbent assay; various statistical analyses performed determine the association between plasma 60-day mortality rate. Results: Compared those healthy controls, critical COVID-19 higher (p < 0.0001). However, there was no statistically significant difference among different > 0.05), resulting from large individual variability. Longitudinal analysis demonstrated that while fluctuated during hospitalization all patients, persistently baseline patients. Cox proportional hazard regression revealed (>260 ng/mL at T1, >1018 T2, >461 T3) Conclusions: Endotheliopathy, marked by glycocalyx degradation occurs nearly infection; increased

Language: Английский

---

Identification of dynamic gene expression profiles during sequential vaccination with ChAdOx1/BNT162b2 using machine learning methods

Frontiers in Microbiology, Journal Year: 2023, Volume and Issue: 14

Published: March 17, 2023

To date, COVID-19 remains a serious global public health problem. Vaccination against SARS-CoV-2 has been adopted by many countries as an effective coping strategy. The strength of the body's immune response in face viral infection correlates with number vaccinations and duration vaccination. In this study, we aimed to identify specific genes that may trigger control under different vaccination scenarios. A machine learning-based approach was designed analyze blood transcriptomes 161 individuals who were classified into six groups according dose timing inoculations, including I-D0, I-D2-4, I-D7 (day 0, days 2-4, day 7 after first ChAdOx1, respectively) II-D0, II-D1-4, II-D7-10 1-4, 7-10 second BNT162b2, respectively). Each sample represented expression levels 26,364 genes. whereas mainly BNT162b2 (Only four received ChAdOx1). deemed labels considered features. Several learning algorithms employed such classification detail, five feature ranking (Lasso, LightGBM, MCFS, mRMR, PFI) applied evaluate importance each gene feature, resulting lists. Then, lists put incremental selection method extract essential genes, rules build optimal classifiers. namely, NRF2, RPRD1B, NEU3, SMC5, TPX2, have previously associated response. This study also summarized describe scenarios help determine molecular mechanism vaccine-induced antiviral immunity.

Language: Английский

---